Jagsonpal Pharmaceuticals Ltd.

NSE: JAGSNPHARM  SECTOR: Pharmaceuticals & Drugs

63.45
-0.25 (-0.39%)

Price Summary

Today's High

₹ 66.5

Today's Low

₹ 63.05

52 Week High

₹ 76.1

52 Week Low

₹ 16

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationAttractive
The stock is considerably attractive based on intrinsic value.
EfficiencyPoor
The company seems highly inefficient in case of asset management.
FinancialsWeak
Watch out! The company might not be able to sustain any adverse condition.

Company Essentials

Market Cap

166.22631 Cr.

Enterprise Value

132.81691 Cr.

No. of Shares

2.6198 Cr.

P/E

16.04

P/B

1.51

Face Value

₹ 5

Div. Yield

0.79%

Book Value (TTM)

₹  41.8825

CASH

38.0742 Cr.

DEBT

4.6648 Cr.

Promoter Holding

70.34%

EPS (TTM)

₹  3.9564

Sales Growth

-4.94995971841253%

ROE

7.8775510612595 %

ROCE

9.53423968257931 %

Profit Growth

4.96368115090201 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1w1m3m6m1Yr3Yr5Yr

* Prices are based on daily market changes.

Valuation Chart 1w1m3m6m1Yr3Yr5Yr

* The chart is based on the standalone earnings of the company.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

Sales Growth (in Cr.)

1 Year-4.95%
3 Year3.3%
5 Year2.8%

Profit Growth (in Cr.)

1 Year9.07%
3 Year-12.79%
5 Year46.38%

ROE%

1 Year7.88%
3 Year1.2%
5 Year3.91%

ROCE %

1 Year9.53%
3 Year2.94%
5 Year6.08%

Debt/Equity

0.0452

Price to Cash Flow

14.78

Interest Cover Ratio

19.3131686442326

CFO/PAT (5 Yr. Avg.)

1.670298867906

Share Holding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Dec 2019 70.34 0
Sep 2019 70.34 0
Jun 2019 70.33 0
Mar 2019 70.26 0
Dec 2018 70.12 0
* Figures given above are % of equity capital

 Strengths

  • Company is virtually debt free.
  • Company has a healthy Interest coverage ratio of 19.3131686442326.
  • The company has an efficient Cash Conversion Cycle of 85.5528499539969 days.
  • Company has a healthy liquidity position with current ratio of 2.89100927826887.
  • The company has a good cash flow management; CFO/PAT stands at 1.670298867906.
  • The company has a high promoter holding of 70.34%.
  • The company has a strong degree of Operating leverage, Average Operating leverage stands at 6.39884653696438.

 Limitations

  • The company has shown a poor profit growth of -12.7857657867383% for the Past 3 years.
  • The company has shown a poor revenue growth of 3.29544792276482% for the Past 3 years.
  • Company has a poor ROE of 1.19587918516856% over the past 3 years.
  • Company has a poor ROCE of 2.93778312226213% over the past 3 years
  • The company has a low EBITDA margin of 2.8741338236473% over the past 5 years.

Quarterly Result (All Figures in Cr.)

PARTICULARS Sep 2019 Dec 2019 Mar 2020 Jun 2020 Sep 2020
Net Sales 41.81 42.01 29.52 31.65 56.35
Total Expenditure 39.3 39.45 28.3 29 51.52
Operating Profit 2.51 2.56 1.22 2.65 4.83
Other Income 0.44 0.65 0.76 0.78 0.41
Interest 0.15 0.1 0.15 0.13 0.12
Depreciation 0.27 0.26 0.32 0.28 0.28
Exceptional Items 0 0 0 0 0
Profit Before Tax 2.54 2.85 1.52 3.03 4.86
Tax 0.51 0.57 -0.04 0.51 0.85
Profit After Tax 2.03 2.28 1.55 2.52 4.01
Adjusted EPS (Rs) 0.08 0.09 0.06 0.1 0.15

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020
Net Sales 143.49 143.87 126.53 166.83 158.57
Total Expenditure 131.68 138.1 137.64 157.49 150.04
Operating Profit 11.81 5.77 -11.11 9.34 8.53
Other Income 0.66 0.47 0.46 1.43 2.53
Interest 5.3 2.64 0.66 0.75 0.51
Depreciation 3.09 1.99 0.32 1.02 1.13
Exceptional Items 0 12.8 0 0 0
Profit Before Tax 4.08 14.4 -11.63 9 9.41
Tax 0.82 2.53 -0.08 1.79 1.54
Net Profit 3.25 11.86 -11.55 7.22 7.87
Adjusted EPS (Rs.) 1.24 4.53 -4.41 2.75 3

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020
Equity and Liabilities
Share Capital 13.1 13.1 13.1 13.1 13.1
Total Reserves 85.27 96.81 84.95 91.37 97.93
Borrowings 0 0 0 0 0
Other N/C liabilities 3.61 3.26 3.19 3.12 3.09
Current liabilities 57.31 29.44 28.58 28.19 32.83
Total Liabilities 159.28 142.61 129.81 135.78 146.95
Assets
Net Block 51.61 21.59 21.32 21.64 22.09
Capital WIP 0 0 0.98 1.89 1.9
Investments 0 0 0 0 11.39
Loans & Advances 6.71 10.9 10.84 12.63 14.32
Other N/C Assets 0 0 2.06 2.06 2.35
Current Assets 100.96 110.11 94.61 97.56 94.91
Total Assets 159.28 142.61 129.81 135.78 146.95
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020
Profit Before Tax 4.08 14.4 -11.63 9 9.41
Adjustment 7.73 -8.63 1.26 0.33 -0.85
Working Capital Changes -1.96 -6.13 8.79 19.71 4.25
Tax Paid -0.82 -2.88 0 1.85 -1.57
Operating Cash Flow 9.04 -3.24 -1.58 30.9 11.25
Investing Cash Flow -2.09 41.29 -3.37 -0.83 -10.76
Financing Cash Flow -6.43 -33.52 -0.6 -6.05 -0.94
Net Cash Flow 0.52 4.53 -5.55 24.02 -0.46

Corporate Actions

Ratings & Research Reports

Company Presentations

Currently we do not have any Presentation and Concall related to this company.
Report us

Company News

Jagsonpal Pharma Stock Price Analysis and Quick Research Report. Is Jagsonpal Pharma an attractive stock to invest in?

 

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Jagsonpal Pharma and its performance over the period of time.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Its cash from the operating activity was Rs 11.247 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Jagsonpal Pharma has a Debt to Equity ratio of 0.0452 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Jagsonpal Pharma , the EPS growth was 9.07638687191403 % which is bad for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Jagsonpal Pharma has OPM of 5.38097898816784 % which is a bad sign for profitability.
     
  • ROE: Jagsonpal Pharma have a poor ROE of 7.8775510612595 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
Brief about Jagsonpal Pharma

X